SUNNYVALE, Calif., Oct. 15, 2024 /PRNewswire/ -- XGIMI, the award-winning leader in home entertainment projectors, is excited to announce the availability of its highly anticipated HORIZON S Series, starting today, October 15th, 2024, on XGIMI.com and Amazon. The new series, which includes the HORIZON S Max and HORIZON S Pro projectors, sets a new standard in home projection with Dual Light 2.0 Technology. This innovative system combines Tri-Color Laser and LED, offering unparalleled brightness, color accuracy, and eye comfort. The HORIZON S Pro is certified by Dolby Vision, while the HORIZON S Max boasts dual certifications with both Dolby Vision and IMAX Enhanced, delivering a true cinematic experience right in your living room.
Both projectors feature a built-in flexible stand with 360° horizontal and 135° vertical rotation, making it easy to adjust the projection angle with just one hand. With 3100 ISO lumens, the HORIZON S Max offers 34.7% more brightness than its predecessor, while the HORIZON S Pro shines with 1800 ISO lumens. Both projectors also include dynamic contrast ratios of 1000000:1 and are equipped with Harman/Kardon speakers for premium audio, ensuring a full cinematic experience with stunning visuals and immersive sound.
Also available today is XGIMI's new modular stand, designed for easy installation with a solid 2.5KG base that ensures stability for your projector, further enhancing the flexibility of the HORIZON S Series. Priced from $1,299 to $1,899, with the added stand retailing for $159, the HORIZON S Series is the ultimate choice for home theater enthusiasts and tech-savvy consumers alike. Consumers can also now purchase XGIMI's new Elfin Flip, a compact long-throw smart projector delivering 1080P resolution and Dolby Audio support, for $399 at XGIMI.com and Amazon.
About XGIMI: Since 2013, the state-of-the-art XGIMI projectors have helped countless people worldwide to create genuinely immersive audio-visual experiences. Working with reputable partners like Google, Harman Kardon, and Texas Instruments, XGIMI builds all-in-one entertainment devices, perfected due to their user-oriented philosophy. Through industry-leading innovation, streamlined setups, and unique designs, XGIMI always strives to develop the best home and portable projectors for everyone to enjoy. Learn more at XGIMI Projector Technology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
XGIMI HORIZON S Series Projectors Now Available
SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas aeruginosa (PsA) pulmonary infections.
MRX-5, a novel benzoxaborole antibiotic, is developed for the treatment of rare chronic pulmonary disease caused by NTM infection. MRX-5 exhibits excellent antibacterial activity against common NTM pathogens and demonstrates good safety in animal trials.MABC affects approximately 12,000 to 20,000 patients in the US and requires treatment durations exceeding 12 months. MRX-5 holds promise for addressing NTM infections.
MRX-8, a novel antibiotic in the polymyxin class, is designed to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxins are limited in clinical use due to high risks of nephrotoxicity and neurotoxicity. MRX-8, with its novel chemical structure, maintains or improves therapeutic efficacy while significantly reducing these risks.
The company also aims to explore the clinical and commercial potential of developing an inhaled formulation targeting chronic lung infections. In mouse models of PsA lung infections, nebulized MRX-8 demonstrated significant reduction in bacterial load in lung tissues, indicating strong bactericidal activity.
At the forum, Dr. Regis Vilchez focused on presenting the development progress and future plans for MRX-5 and MRX-8, while analyzing the significant market demand for treatments targeting NTM lung disease and chronic PsA pulmonary infections. These two pipeline products are expected to fill gaps in the treatment of NTM lung disease and chronic PsA pulmonary infections, offering patients safer and more effective new treatment options.
MicuRx Pharmaceuticals remains committed to discovering, developing, and commercializing innovative medicines to meet unmet clinical needs, providing patients with differentiated therapeutic solutions. The company will continue to actively advance the development of MRX-5 and MRX-8, aiming to bring these innovative drugs to market as soon as possible, bringing hope to patients worldwide.
For more information, please contact:
MicuRx Pharmaceuticals, Inc.
Website: www.micurx.com
About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of multidrug-resistant infections. With a mission to address significant unmet medical needs, MicuRx is advancing a portfolio of drug candidates targeting difficult-to-treat infections.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
